Trials / No Longer Available
No Longer AvailableNCT01728051
Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver
An Open Label, Expanded Access Study of Melphalan Chemosaturation With the Delcath System in Patients With Ocular and Cutaneous Melanoma Metastatic to the Liver
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Delcath Systems Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The safety and efficacy of CS-PHP-melphalan has been evaluated in a phase 3 trial conducted in the same patient population as well as using the same melphalan dosing as proposed in this study. This expanded access protocol will provide an experimental alternative treatment option for both physicians and patients until the Delcath CS-PHP System receives marketing approval.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Melphalan | |
| DEVICE | Percutaneous Hepatic Perfusion |
Timeline
- First posted
- 2012-11-16
- Last updated
- 2013-10-23
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01728051. Inclusion in this directory is not an endorsement.